 Barbara Frederick
Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 11 | 2020 | 427 | 1.450 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2020 | 68 | 0.830 |
Why?
| | Phthalazines | 2 | 2020 | 38 | 0.740 |
Why?
| | Cetuximab | 2 | 2020 | 90 | 0.730 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 40 | 0.700 |
Why?
| | DNA Repair | 2 | 2020 | 184 | 0.680 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 332 | 0.660 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 385 | 0.640 |
Why?
| | Piperazines | 2 | 2020 | 310 | 0.640 |
Why?
| | Quinazolines | 3 | 2007 | 240 | 0.540 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2014 | 577 | 0.530 |
Why?
| | ErbB Receptors | 5 | 2020 | 554 | 0.480 |
Why?
| | Peptides, Cyclic | 3 | 2020 | 252 | 0.350 |
Why?
| | Mice, Nude | 7 | 2020 | 628 | 0.340 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2020 | 695 | 0.320 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2007 | 103 | 0.320 |
Why?
| | Cell Line, Tumor | 11 | 2020 | 2699 | 0.310 |
Why?
| | Piperidines | 2 | 2007 | 159 | 0.290 |
Why?
| | Mesoderm | 1 | 2007 | 138 | 0.260 |
Why?
| | Smad4 Protein | 2 | 2020 | 34 | 0.260 |
Why?
| | Neoplasms | 4 | 2023 | 2089 | 0.250 |
Why?
| | Combined Modality Therapy | 5 | 2020 | 1117 | 0.250 |
Why?
| | Angiogenesis Inhibitors | 1 | 2006 | 213 | 0.230 |
Why?
| | Neovascularization, Pathologic | 1 | 2006 | 280 | 0.220 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2007 | 637 | 0.210 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2008 | 959 | 0.200 |
Why?
| | Epithelial Cells | 1 | 2007 | 946 | 0.190 |
Why?
| | High-Throughput Screening Assays | 1 | 2023 | 123 | 0.190 |
Why?
| | DNA End-Joining Repair | 1 | 2020 | 15 | 0.180 |
Why?
| | Proof of Concept Study | 1 | 2020 | 47 | 0.180 |
Why?
| | Clone Cells | 1 | 2020 | 247 | 0.170 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 155 | 0.170 |
Why?
| | Drug Synergism | 1 | 2020 | 315 | 0.170 |
Why?
| | Drosophila melanogaster | 2 | 2012 | 188 | 0.170 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 42 | 0.170 |
Why?
| | Prostatic Neoplasms | 3 | 2013 | 913 | 0.160 |
Why?
| | Cisplatin | 1 | 2020 | 262 | 0.160 |
Why?
| | Lung Neoplasms | 2 | 2008 | 2159 | 0.150 |
Why?
| | Mice | 9 | 2020 | 14847 | 0.150 |
Why?
| | Radiation, Ionizing | 3 | 2012 | 71 | 0.140 |
Why?
| | Apoptosis | 4 | 2020 | 2349 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1144 | 0.140 |
Why?
| | DNA Damage | 3 | 2020 | 351 | 0.140 |
Why?
| | Animals | 14 | 2020 | 31570 | 0.130 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 327 | 0.130 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2015 | 38 | 0.120 |
Why?
| | Stromal Cells | 1 | 2014 | 96 | 0.110 |
Why?
| | N-Glycosyl Hydrolases | 2 | 2004 | 5 | 0.110 |
Why?
| | Radiation Tolerance | 1 | 2014 | 92 | 0.110 |
Why?
| | Adherens Junctions | 1 | 2013 | 26 | 0.110 |
Why?
| | Signal Transduction | 6 | 2014 | 4501 | 0.110 |
Why?
| | Plant Proteins | 2 | 2004 | 81 | 0.110 |
Why?
| | Hedgehog Proteins | 1 | 2014 | 172 | 0.110 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2012 | 181 | 0.110 |
Why?
| | Sulfones | 1 | 2013 | 97 | 0.100 |
Why?
| | Exosomes | 1 | 2013 | 92 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2020 | 3499 | 0.100 |
Why?
| | Prostate | 1 | 2013 | 157 | 0.100 |
Why?
| | Glycine | 1 | 2013 | 152 | 0.100 |
Why?
| | Radiation-Protective Agents | 1 | 2012 | 26 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1356 | 0.100 |
Why?
| | Metalloporphyrins | 1 | 2012 | 103 | 0.100 |
Why?
| | Radiotherapy | 1 | 2012 | 175 | 0.090 |
Why?
| | Stilbenes | 1 | 2011 | 36 | 0.090 |
Why?
| | Maytansine | 1 | 2011 | 13 | 0.090 |
Why?
| | Autocrine Communication | 1 | 2011 | 42 | 0.090 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2011 | 63 | 0.090 |
Why?
| | Paclitaxel | 1 | 2012 | 190 | 0.090 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 438 | 0.090 |
Why?
| | Prostaglandin D2 | 1 | 2009 | 21 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2007 | 86 | 0.080 |
Why?
| | Antioxidants | 1 | 2012 | 529 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2009 | 742 | 0.080 |
Why?
| | Humans | 19 | 2023 | 114080 | 0.080 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2009 | 122 | 0.080 |
Why?
| | Up-Regulation | 2 | 2014 | 802 | 0.070 |
Why?
| | Glutathione | 1 | 2009 | 293 | 0.070 |
Why?
| | Hypoxia | 1 | 2013 | 956 | 0.070 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2011 | 182 | 0.070 |
Why?
| | Receptors, LHRH | 2 | 2004 | 14 | 0.070 |
Why?
| | Respiratory Mucosa | 1 | 2009 | 252 | 0.070 |
Why?
| | Cortactin | 1 | 2006 | 7 | 0.070 |
Why?
| | Actin-Related Protein 2-3 Complex | 1 | 2006 | 8 | 0.070 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2006 | 57 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2008 | 278 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 2 | 2008 | 613 | 0.060 |
Why?
| | Cell Division | 1 | 2007 | 754 | 0.060 |
Why?
| | Protein Biosynthesis | 3 | 2015 | 386 | 0.060 |
Why?
| | Drug Delivery Systems | 2 | 2008 | 295 | 0.060 |
Why?
| | Female | 5 | 2020 | 59349 | 0.060 |
Why?
| | Immunotoxins | 1 | 2004 | 33 | 0.060 |
Why?
| | Cell Cycle | 2 | 2020 | 541 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 784 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2003 | 189 | 0.050 |
Why?
| | Drug Discovery | 1 | 2023 | 123 | 0.050 |
Why?
| | Carcinoma | 1 | 2003 | 198 | 0.050 |
Why?
| | Mutation | 4 | 2013 | 3338 | 0.050 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | Antineoplastic Agents | 2 | 2008 | 1875 | 0.040 |
Why?
| | HCT116 Cells | 2 | 2011 | 70 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 127 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 243 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 187 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 845 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2020 | 2173 | 0.040 |
Why?
| | Cell Line | 1 | 2023 | 2629 | 0.040 |
Why?
| | Transfection | 2 | 2011 | 863 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2764 | 0.030 |
Why?
| | Veratrum Alkaloids | 1 | 2014 | 17 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 21 | 0.030 |
Why?
| | Cell Survival | 2 | 2011 | 1014 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 36 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 850 | 0.030 |
Why?
| | Ribosome Inactivating Proteins, Type 1 | 2 | 2004 | 3 | 0.030 |
Why?
| | Annexin A2 | 1 | 2013 | 10 | 0.030 |
Why?
| | Tetraspanins | 1 | 2013 | 15 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 563 | 0.030 |
Why?
| | Metalloproteases | 1 | 2013 | 37 | 0.030 |
Why?
| | CHO Cells | 2 | 2004 | 137 | 0.030 |
Why?
| | Models, Biological | 2 | 2012 | 1611 | 0.030 |
Why?
| | Cricetinae | 2 | 2004 | 252 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 198 | 0.030 |
Why?
| | Heat-Shock Proteins | 1 | 2013 | 112 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 76 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2014 | 167 | 0.030 |
Why?
| | Blotting, Western | 2 | 2007 | 1143 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2013 | 101 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2013 | 221 | 0.030 |
Why?
| | Penis | 1 | 2012 | 37 | 0.030 |
Why?
| | Erectile Dysfunction | 1 | 2012 | 38 | 0.030 |
Why?
| | Glioma | 1 | 2015 | 285 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 3315 | 0.020 |
Why?
| | Testis | 1 | 2012 | 133 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 359 | 0.020 |
Why?
| | Comet Assay | 1 | 2011 | 18 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 328 | 0.020 |
Why?
| | BRCA1 Protein | 1 | 2011 | 56 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2011 | 82 | 0.020 |
Why?
| | Immunoblotting | 1 | 2011 | 282 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2011 | 3862 | 0.020 |
Why?
| | Spindle Apparatus | 1 | 2011 | 87 | 0.020 |
Why?
| | Larva | 1 | 2011 | 191 | 0.020 |
Why?
| | Proteome | 1 | 2013 | 337 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 164 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 261 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 607 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 549 | 0.020 |
Why?
| | tert-Butylhydroperoxide | 1 | 2009 | 10 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 863 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 322 | 0.020 |
Why?
| | Cytoprotection | 1 | 2009 | 51 | 0.020 |
Why?
| | Biological Products | 1 | 2012 | 166 | 0.020 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2008 | 10 | 0.020 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2008 | 10 | 0.020 |
Why?
| | GRB2 Adaptor Protein | 1 | 2008 | 12 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 350 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2009 | 137 | 0.020 |
Why?
| | Skin | 1 | 2012 | 653 | 0.020 |
Why?
| | Luciferases | 1 | 2008 | 142 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2011 | 393 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1206 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2015 | 966 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2008 | 256 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2009 | 465 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2182 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2011 | 445 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1624 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1526 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 227 | 0.020 |
Why?
| | Histones | 1 | 2011 | 529 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2008 | 771 | 0.020 |
Why?
| | Gene Amplification | 1 | 2006 | 95 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 367 | 0.020 |
Why?
| | Male | 4 | 2013 | 55420 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2006 | 308 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2006 | 486 | 0.020 |
Why?
| | Rats | 1 | 2012 | 4913 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2007 | 1144 | 0.010 |
Why?
| | Actins | 1 | 2006 | 376 | 0.010 |
Why?
| | Colony-Forming Units Assay | 1 | 2004 | 88 | 0.010 |
Why?
| | Tumor Stem Cell Assay | 1 | 2003 | 33 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2004 | 147 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2009 | 1068 | 0.010 |
Why?
| | Drug Combinations | 1 | 2003 | 286 | 0.010 |
Why?
| | Cattle | 1 | 2004 | 918 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2003 | 735 | 0.010 |
Why?
| | Cell Membrane | 1 | 2004 | 670 | 0.010 |
Why?
| | Protein Binding | 1 | 2004 | 1888 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2003 | 2550 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2008 | 9051 | 0.010 |
Why?
|
|
Frederick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|